Daily Dose - Dec 19th, 2024
Daily Dose |
View online
December 19, 2024
CDMO sector looks to recovery in 2025 amid positive macro, industry trends
While 2024 was a “mixed bag” for contract development and manufacturing organizations, a rosier picture is emerging for next year.
Read More
Shortage of Lilly’s blockbuster drugs Mounjaro, Zepbound is resolved: FDA
The regulator on Thursday confirmed that Eli Lilly’s injectable tirzepatide, the active ingredient in Mounjaro for type 2 diabetes and Zepbound for obesity, is not in shortage.
Read More
Nirsum Labs selects Lifecore Biomedical for CDMO services for OUD, AUD candidate
Lifecore will support Nirsum’s lead development candidate, NRS-033, a novel treatment for opioid use disorder and alcohol use disorder.
Read More